Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
about
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot studyA recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.IgE-based immunotherapy of cancer: challenges and chances.The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity.IgA function--variations on a theme.7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) bindingAnti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.Neutrophils in antibody-based immunotherapy of cancer.Naturally occurring structural isomers in serum IgA1 o-glycosylation.Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.Immunoglobulin A: A next generation of therapeutic antibodies?Structure and function relationships in IgA.Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.IgA antibody production by intrarectal immunization of mice using recombinant major capsid protein of hamster polyomavirusThe multiple facets of FcRn in immunity.Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.IgA EGFR antibodies mediate tumour killing in vivo.Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells.Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines.A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies.An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.Keystone symposia: antibody-based therapeutics for cancer.
P2860
Q28270899-9C861F3A-2306-4CA3-92B7-9DF5804F26F0Q33200753-F2760B98-E732-4E25-B129-CD976D109ADEQ33619979-C98B876F-797E-4A2D-9DBE-63226ED24275Q34218284-F6BF448B-788D-4A51-8F3B-456C44CE8CECQ35893307-8EF7ECC1-98F3-415B-BD6C-BB0D058D5A3AQ35992488-A32359E4-5B31-4DD2-8FB6-925BC16A7477Q36127055-5A0DC186-62AA-43F0-834D-C72DBE437345Q36216363-0AE31BF3-27A3-4E5C-871A-B6EFCC528499Q36366594-17F2EF65-B010-43FF-9C5F-5BC3CF68B15DQ37032641-47D819BA-2B10-43E3-B16C-8E67AEE6FF2EQ37352215-7AB6D358-5B61-450D-A98F-921BEE48C43CQ37468539-79AB7048-9B01-4727-BDB9-1AF5FD7EFDDFQ37892323-B2952BDE-D5A4-4F99-BBD1-CC25B77CEFB9Q37936765-784C9E31-F907-4489-AC64-C8FD46A01303Q37964490-53228203-9C25-4404-849F-9D60334627EBQ38408955-A2908AA5-5473-4FC6-A6B9-C1D1821FF74EQ38615385-201EAD3C-F347-4B9C-907C-40D8C05E72FEQ39027573-98F6D13E-EC44-46E4-A73B-A9CBCF687EC8Q39114924-47D83E49-8FB1-41BD-843B-56421AD48058Q39358478-EE130600-6773-47B8-9CA1-6775450E34A1Q39515308-0C0FE963-C27A-494F-8F7D-D948E0C9A0E9Q39709073-9E1FEE06-DFEF-45AB-AD26-1FE186834E85Q40375510-D42FAC4A-C304-4E52-82BD-DEC1B2FA91EAQ41704272-27DB5A10-1E2D-458D-BD8F-1B6D1FE6DEC0Q42372842-054E30F6-C3A7-4C82-81B7-21E1B93ABF3FQ45106203-95F4C07A-3488-4F9A-8975-990DE72CD2A2Q53126117-38D6CB77-A274-413A-A4A8-7EB4580A95BEQ53303155-5B470814-35D5-41D4-8DDC-E631B5AD6D62
P2860
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
@en
type
label
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
@en
prefLabel
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
@en
P2093
P1433
P1476
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
@en
P2093
Bernhard Stockmeyer
Gestur Vidarsson
Jan G J van De Winkel
Martin Gramatzki
Martin J Glennie
Michael Dechant
Roland Repp
Thomas Valerius
P304
P356
10.1182/BLOOD-2002-03-0687
P407
P577
2002-08-08T00:00:00Z